Clinical trials: Acute Cardiac Syndrome
Acute Coronary Syndrome
A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)
The purpose of this study is determine if SCH 530348 2.5 mg tablets containing a high percentage of drug as the free base are equivalent to tablets with the standard percentage when given to participants.
- Trial name
- NCT01358344
- Testing
- Pantoprazole, SCH 530348 (high percentage), SCH 530348 (standard percentage)
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome
Comparative Pharmacokinetics of YH14659
The objective of this study is to compare pharmacokinetics after single oral administration of 2 capsules of YH14659, a fixed-dose combination of clopidogrel and aspirin developed by Yuhan Corporation versus co-administration of…
- Trial name
- YH14659 (NCT01422109)
- Testing
- YH14659, clopidogrel & aspirin
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Acute Coronary Syndrome
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is…
- Trial name
- NCT00296387
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 102 sites in Belgium, Canada and 9 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome, Coronary Artery Stenosis
Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization
This is a multicenter, prospective trial to measure the test performance characteristics of the Magnetocardiography (MCG) CardioFlux cardiac diagnostic system in detecting clinically significant coronary artery obstruction in…
- Conditions
- Acute Coronary Syndrome, Coronary Artery Stenosis, Myocardial Ischemia
- Trial name
- NCT04044391
- Testing
- CardioFlux Magnetocardiograph
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Genetesis Inc.
Atherosclerosis, Acute Coronary Syndrome (ACS)
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a…
- Trial name
- Platform (NCT00385138)
- Testing
- Cangrelor, clopidogrel
- Where
- United States
- Volunteers
- 5,364 people
- Sponsor
- The Medicines Company
Chronic Coronary Syndrome, Coronary Artery Disease
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and…
- Conditions
- Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- FOCUS DL (NCT06186336)
- Testing
- Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- GE Healthcare
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Stable Angina, Silent Myocardial Ischemia
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in…
- Conditions
- Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome
- Trial name
- SENIOR (NCT02099617)
- Testing
- Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
- Where
- 44 sites in Belgium, Finland and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Ceric Sàrl
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Coronary Arterial Disease (CAD), Plaque
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
ICECAP is a multi-centre, prospective, single-arm, interventional, traditional feasibility clinical investigation to evaluate the efficacy and safety of intra-coronary cryotherapy on vulnerable or high-risk plaque (HRP), using…
- Conditions
- Coronary Arterial Disease (CAD), Plaque, Vulnerable Plaque, Cryotherapy
- Trial name
- ICECAP (NCT06939374)
- Testing
- Intracoronary Cryotherapy
- Where
- 3 sites in Belgium, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cryotherapeutics SA
Coronary Artery Disease, Acute Coronary Syndrome
Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment
The objective of GIANT Study is to evaluate the clinical impact of genetic resistance to thienopyridine profile determination (CYP2C19 gene) and the clinical impact of compliance to an adjusted thienopyridine treatment on STEMI…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Genetic Resistance to Clopidogrel, Compliance to Thienopyridine Treatment
- Trial name
- GIANT (NCT01134380)
- Where
- 12 sites in France
- Volunteers
- 1,500 people
- Sponsor
- Biotronik France
Dyslipidemia, Atherosclerosis
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
- Conditions
- Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
- Trial name
- NCT00768274
- Testing
- RVX000222
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Resverlogix Corp
Acute Coronary Syndrome
Phase I Study of GW856553 (Losmapimod)
This study is the first study of losmapimod in Japanese subjects. This study will be a single-center, single blind, phase I and two part study to characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profiles…
- Trial name
- NCT01648192
- Testing
- Losmapimod for single dose, Losmapimod for repeat dose
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Trial name
- AReMIS (NCT01952392)
- Where
- France
- Volunteers
- 4,992 people
- Sponsor
- AstraZeneca
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
"Discovery2" Study of Using MCG at Emergency Departments
The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain.
- Conditions
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
- Trial name
- Discovery2 (NCT07822581)
- Testing
- Magnetocardiography
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- SB Technology, Inc.
Thromboembolism
Michelangelo - Oasis 5
Study Objectives PRIMARY OBJECTIVE: To evaluate whether fondaparinux is at least as effective as or superior to enoxaparin in preventing death, myocardial infarction or refactory ischemia up to Day 9 in the acute treatment of…
- Trial name
- NCT00139815
- Testing
- Fondaparinux, enoxaparin
- Volunteers
- 20,078 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disorder
Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)
Collecting local data, safety and experience trial.
- Trial name
- NCT00652717
- Testing
- Ezetimibe, simvastatin
- Volunteers
- 280 people
- Sponsor
- Organon and Co
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction
Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
The aim of REHAB trial is to investigate the impact of early mobilization after AMI in reducing left ventricular remodeling, as assessed by cardiac magnetic resonance imaging.
- Conditions
- Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction, Systemic Inflammation, Ventricular Remodeling
- Trial name
- NCT04161378
- Testing
- Cardiac imaging, Laboratory analysis
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center